Overview

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care

Status:
Not yet recruiting

Trial end date:
2023-05-15

Target enrollment:

Participant gender:

Summary

Objective: To evaluate non-inferiority of Trimbow, an approved therapy for treatment of severe COPD, in ICU compared to the standard of care which is based on the same therapeutic approach. Study location: CHU Sart-Tilman, 4000 Liège, Belgium Study duration: 2 years Type : Interventional Methodology: Prospective clinical trial Number of patients: 200 (randomized 1:1) Main Inclusion criteria : - Maintenance therapy (LAMA or LABA) for COPD - Age >18 - Admission for AE of COPD - Signed Inform consent - Admitted in ICU >24h

Phase:

Phase 4

Details

Lead Sponsor:

PARZIBUT Gilles

Treatments:

Beclomethasone
Formoterol Fumarate
Glycopyrrolate